Actuality

 SOFIA, Bulgaria, August 12, 2009. -- Doverie Hospital announced that on 11 August, 2009 it executed a master clinical research partnership agreement with Crossover CRI AG ("Crossover"), a leading provider of clinical research support staff and services to healthcare institutions.

Dr. Peter Keremedchiev, Executive Director of Doverie Hospital said: “Our hospital offers state-of-the-art medical care. Participating in clinical trials of international importance is a key mission of our doctors and nursing staff. Patients come to Doverie Hospital also because they know they can find access to drugs and devices which are not accessible yet outside clinical trials. Our collaboration with Crossover will boost the image of our hospital with pharmaceutical and biotechnology companies internationally.”

According to Dr. Jean-Pierre Tassignon, President & CEO of Crossover, “The Crossover Clinical Research Unit (CRU) at Doverie Hospital is the first investment of Crossover in Eastern Europe, which plays an increasingly important role in clinical research. Crossover is confident that clinical research at Doverie Hospital will develop rapidly because the global clinical research market needs elite hospitals with the equipment and talent to conduct modern clinical trials.” He sees synergistic effects with the large CRU Crossover has already set up at CHU Brugmann hospital and the HUDERF pediatric hospital in Brussels, Belgium.

 Clinical trials now involve a lot of genomic and proteomic research parameters and electronic data transfer. The Crossover office in Bulgaria headed by Dr Velizar Tchernev will provide key support to the new CRU.